Skip to main content

Table 2 Validations of predicted drug-PPI interactions

From: DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing

Drug Name Protein #1 (direct binding partner) Protein #2 (PPI) Reference
Bicalutamide ABL1 CASP9 Danquah et al. Pharm Res. 26(9):2081–92. (2009) [38]
  ABL1 CCNA2 Katayama et al. Int J Oncol. 36(3):553–62. (2010) [39]
  ABL1 MAPK11 Malinowska et al. Endocr Relat Cancer. 16:155–169. (2009) [40]
Cladribine ADA DCK Sasvári-Székely et al. Biochem Pharmacol. 56(9):1175–1179. (1998) [41]
Chlordiazepoxide AKT1 NR3C1 Curtin et al. Brain Behav, Immun. 23(4): 535–547. (2009) [42]
Progeterone AR F2 Oger et al. Arterioscler Thromb Vasc Biol. 23:1671–1676. (2003) [43]
Cyproterone AR CASP3 Eckle et al. Toxicol Pathol. 32:9–15. (2004) [44]
  AR NR3C1 Honer et al. Mol Pharmacol. 63(5):1012–1020. (2003) [45]
Telmisasrtan BCL2 IL2 Syrbe et al. Hypertens Res. 30(6):521–527. (2007) [46]
Sorafenib BRAF PRKCQ Jane et al. J Pharmacol Exp Ther. 319(3):1070–1080. (2006) [47]
Methotrexate DHFR CDK2 Maddika et al. J Cell Sci. 121:979–988. (2008) [48]